The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma
Zeitschrift für Gastroenterologie · 01.01.2023 · 61 (01) · e23
DOI: 10.1055/s-0042-1759967 ↗Kurz gefasst
Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.01.2023. Verfasst von Hamish Innes und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Background
The genetic factors associated with survival following diagnosis of hepatocellular carcinoma (HCC) are not well understood. The goal of this study was to assess if polymorphisms influencing susceptibility to HCC are also associated with HCC prognosis.
Methods
United Kingdom Biobank participants diagnosed with HCC after study enrolment were included. The primary outcome event was all-cause mortality. Patients were followed from the date of HCC diagnosis to death or the registry completion date. Five HCC susceptibility polymorphisms were considered: rs738409 (PNPLA3), rs58542926 (TM6SF2); rs72613567 (HSD17B13); rs2242652 (TERT) and rs708113 (WNT3A). Cox regression was used to determine the independent association between these genetic loci and HCC mortality risk. All models included adjustment for age at HCC diagnosis, gender, ethnicity, receipt of curative HCC treatment, severity of underlying liver disease, and liver disease aetiology. Sensitivity analyses were performed using liver-related mortality and HCC mortality as alternative outcome events.
Results
The final sample included 439 patients with an average of 1.9 years follow-up per patient. There were 321,295 and 235 all-cause, liver-related and HCC-related deaths. The 3-year all-cause mortality proportion was: 68.8% (95%CI: 64.1-73.3). In multivariate analysis, rs72613567:TA (HSD17B13) was the only genetic susceptibility variant associated with liver-related mortality (aHR:0.76; 95%CI:0.62-0.92; P=0.005). Other factors associated were Baveno stage 3/4 (aHR:1.65; 95%CI:1.06-2.59; P=0.03) and HCC treatment with curative intent (aHR:0.25; 95%CI: 0.17-0.37; P
Zitieren
APA
Innes, H., Hamill, V., Hutchinson, S., Stickel, F., Hampe, J., Morgan, M. Y., & Buch, S. (2023). The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma. Zeitschrift für Gastroenterologie, 61(01), e23. https://doi.org/10.1055/s-0042-1759967
Vancouver
Innes H, Hamill V, Hutchinson S, Stickel F, Hampe J, Morgan MY, et al. The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma. Zeitschrift für Gastroenterologie. 2023;61(01):e23. doi:10.1055/s-0042-1759967
BibTeX
@article{Innes2023,
author = {Innes, Hamish and Hamill, Victoria and Hutchinson, Sharon and Stickel, Felix and Hampe, Jochen and Morgan, Marsha Y. and Buch, Stephan},
title = {The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma},
journal = {Zeitschrift für Gastroenterologie},
year = {2023},
volume = {61},
number = {01},
pages = {e23},
doi = {10.1055/s-0042-1759967}
}
EUVIMED